Drug Database
ZO

zolpidem tartrate (Intermezzo / zolpidem, TransOral)

✓ Approved

Transcept Pharmaceuticals · GABRA1 · Small Molecule

What is zolpidem tartrate?

zolpidem tartrate is a small molecule developed by Transcept Pharmaceuticals. It is approved for therapeutic indications via oral (po) or sublingual (sl)/oral transmucosal.

Drug Profile

Brand NamesIntermezzo, zolpidem, TransOral
CompanyTranscept Pharmaceuticals
Drug ClassSmall Molecule
Molecular TargetGABRA1
RouteOral (PO), Sublingual (SL)/Oral Transmucosal
StatusApproved

Mechanism of Action

Molecular Targets

zolpidem tartrate acts on 1 molecular target:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (DEE19, ECA4)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

zolpidem tartrate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersInsomnia✓ Approved

Related Research Articles

PubMedJournal of the science of food and agriculture2026-10-15

Cerasus humilis proanthocyanidins alleviate osteoporosis by regulating renal calcium metabolism.

Li Xinran X, Shu Yanxia Y, Yu Chao C, Feng Weiran W et al.

Postmenopausal osteoporosis is associated with disturbed calcium homeostasis and renal calcium handling. Although Cerasus humilis proanthocyanidins (PA) show anti-osteoporotic activity, their effects on renal calcium metabolism remain unclear. We hypothesized that C. humilis PA could alleviate ovariectomy (OVX)-induced bone loss by improving renal calcium reabsorption. Compared with untreated OVX rats, 12 weeks of PA treatment increased bone mineral density from 125.5 to 232.8 mg cm-3 and improved trabecular microarchitecture (P < 0.05). PA reduced β-C-terminal telopeptide and tartrate-resistant acid phosphatase-5b levels, increased bone-specific alkaline phosphatase levels, decreased 24 h urinary calcium excretion, and increased apparent calcium absorption from 50.4% to 87.8% (all P < 0.05). Renal histopathological alterations were attenuated, with increased renal bone morphogenetic protein-7 and urinary Klotho levels and decreased serum fibroblast growth factor 23 levels. Renal protein expression of transient receptor potential vanilloid 5 (TRPV5) and Calbindin-D28k increased by 53.0% and 45.6%, respectively (P < 0.05), with corresponding mRNA upregulation. C. humilis PA alleviated OVX-induced bone loss and calcium metabolic disturbances. The effects were associated with reduced urinary calcium loss and increased renal TRPV5 and Calbindin-D28k expression. Renal calcium handling may therefore contribute to the anti-osteoporotic effect of C. humilis PA in OVX rats, and the potential as a dietary ingredient for bone health warrants further investigation. © 2026 Society of Chemical Industry.

PubMedEuropean spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society2026-10-15

Multifactorial prediction of mechanical complications after lumbar fusion using bone quality and turnover markers.

Ogura Yoji Y, Kato Taisei T, Nishiyama Yuichiro Y, Varthi Arya A et al.

To evaluate the predictive value of preoperative bone health indices including T-score, bone mineral density (BMD), Hounsfield units (HU), and serum bone turnover markers for postoperative mechanical complications following lumbar fusion surgery. This retrospective study analyzed prospectively collected data from 120 patients who underwent lumbar fusion with pedicle screw instrumentation between August 2021 and June 2024. Preoperative assessments included dual-energy X-ray absorptiometry (DEXA)-derived BMD and T-scores, computed tomography-derived HU values, and serum bone turnover markers including procollagen type I N-terminal propeptide (P1NP) and tartrate-resistant acid phosphatase type 5b (TRACP-5b). Mechanical complications were evaluated radiographically at ≥ 12 months postoperatively. Receiver operating characteristic (ROC) curve analyses were performed for individual parameters, and multivariable logistic regression was used to identify independent predictors. Mechanical complications occurred in 40 patients (33%). In univariate analysis, patients with complications were significantly older and had lower femoral BMD and T-scores and higher P1NP levels (all p < 0.05). ROC analysis demonstrated modest predictive ability for femoral T-score (AUC = 0.688) and BMD (AUC = 0.681). In multivariable logistic regression, TRACP-5b (OR = 1.02, p = 0.042) and the number of fused levels (OR = 5.24, p = 0.001) were associated with complications. A multivariate model combining significant variables yielded an AUC of 0.830, indicating good overall discrimination. Preoperative T-score, BMD, and HU values alone showed limited predictive accuracy for mechanical complications after lumbar fusion. However, integrating serum bone turnover markers and surgical factors substantially improved predictive performance. A multifactorial preoperative assessment incorporating bone density, metabolic, and mechanical parameters may better stratify risk and guide surgical planning in patients with poor bone quality.

PubMedMagnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine2026-10-14

Sleep-related Brain Activity in an Arousal-reducing Agent-induced Mouse Model Evaluated with fMRI.

Tamada Hanabi H, Hata Junichi J, Muta Kanako K, Oshiro Hinako H et al.

Functional MRI (fMRI) has been established as a technique for capturing functional changes based on brain activity and is widely used to evaluate various diseases and physiological conditions. However, studies that systematically evaluate functional brain networks during arousal-reducing agent-induced sleep in mice by using resting-state fMRI (rsfMRI) are limited. This study aimed to compare and analyze whole-brain functional connectivity (FC) and reorganization patterns of large-scale brain functional networks in the mouse brain during arousal-reducing agent-induced sleep, focusing on arousal-reducing agents acting on different arousal regulatory systems. Sixteen healthy male C57BL/6JmsSlc mice (aged 16.4 ± 8.7 week) were used in this study. The mice were assigned to 4 groups: control, zolpidem (20 mg/kg), lemborexant (40 mg/kg), and dexmedetomidine (75 μg/kg). rsfMRI was performed using a 9.4T MRI system equipped with an 86 mm volume transmit coil and an 8-channel receive-only coil (Bruker BioSpin, Ettlingen, Baden-Württemberg, Germany). After head post-surgery and habituation, blood oxygenation level-dependent (BOLD) images were acquired using a gradient-echo echo-planar imaging (GRE-EPI) sequence (TR/TE = 1500/14 ms). Each mouse underwent six 10 min imaging sessions. fMRI data were preprocessed using Statistical Parametric Mapping (SPM12; Wellcome Centre for Human Neuroimaging, London, UK) and analyzed using the CONN FC toolbox (McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA). ROI × ROI FC matrices were calculated for each fMRI session. Group differences were assessed using linear mixed-effects models that accounted for repeated measurements within animals, individual variability, and age differences among groups. Compared to the control group, the zolpidem group showed the smallest overall differences, whereas the dexmedetomidine group showed the largest differences. Furthermore, although relatively similar trends were observed between the groups in the distribution of mean correlation coefficients within each network, different trends were observed between the networks. In addition to network reorganization associated with the sleep-inducing state, which is commonly observed regardless of the arousal-reducing agent type, distinct network changes exhibiting arousal-reducing agent-specific connectivity patterns were observed.

PubMedExpert opinion on pharmacotherapy2026-10-14

Current perspectives on the pharmacotherapeutic management of insomnia in Veterans.

Saliba Ranime R, Cercone Julia J, El-Solh Ali A AA

Insomnia is a highly prevalent sleep disorder among Veterans and frequently co-occurs with post-traumatic stress disorder (PTSD), depression, chronic pain, and substance use disorders. This review synthesizes the current evidence on pharmacological management of insomnia in Veterans with attention to guideline recommendations, veteran-specific safety considerations, and comorbidity-driven prescribing. We discuss the rationale for reducing long-term reliance on benzodiazepines and benzodiazepine receptor agonists (BZRAs) in favor of agents with more favorable long-term risk profiles. Concurrent prescribing of GABAergic hypnotics with opioids is addressed in the context of existing VA Opioid Safety Initiative policy, FDA labeling, and observational overdose data. Off-label agents such as trazodone and quetiapine continue to be widely used despite limited efficacy evidence for insomnia; their use is best reserved for cases in which better-supported options have failed. Contemporary guidance places cognitive behavioral therapy for insomnia as first-line treatment, while pharmacotherapy is reserved for patients who do not respond to, cannot access, or decline behavioral treatment. The 2025 VA/DoD guideline suggests several medications when pharmacotherapy is used, including daridorexant, doxepin, eszopiclone, lemborexant, suvorexant, zaleplon, and zolpidem, and recommends against antipsychotics, benzodiazepines, and trazodone for chronic insomnia disorder.

PubMedBJPsych open2026-10-13

Zolpidem for Catatonia Refractory to Benzodiazepines in Resource-Limited Settings - CORRIGENDUM.

Hodge Holly H, Ullahansari Shaikh S, Berry Blake B, Oyeka Michelle M

PubMedJournal of orthopaedic translation2026-10-13

MRSA-dominant colonization and synergistic pathogenicity with Pseudomonas aeruginosa in a polymicrobial bone infection model.

Zhou Hang H, Liu Wanchang W, Peng Xinliang X, Li Maohui M et al.

Polymicrobial bone infections (PBI) remain difficult to treat due to multi-drug resistance and poorly defined microbial interactions. Co-infection with methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (PA) represents a clinically prevalent subtype of PBI. Using a rat PBI model, this study aimed to elucidate the spatiotemporal dynamics of MRSA-PA co-infection and its impact on host responses, bacterial persistence, and antimicrobial susceptibility. Titanium screws were pre-contaminated with fluorescently labeled MRSA (mCherry) or PA (green fluorescent protein, GFP) and implanted 5 mm apart into the femoral mid-diaphysis of Sprague-Dawley rats. Animals were assigned to five groups: sterile, MRSA, PA, MRSA + PA, and PA + MRSA. Longitudinal evaluation included hematology, serum biochemistry (CRP, PCT, TNF-α, and IL-6), micro-CT imaging, and hard-tissue sectioning. Colony-forming unit (CFU) counts and histological analyses (H&E, Gram, and DAPI staining) were performed to evaluate bacterial burden, spatiotemporal colonization and biofilm formation. Local inflammation and osteoclast activation were further assessed by TNF-α immunohistochemistry and tartrate-resistant acid phosphatase (TRAP) staining. Antimicrobial susceptibility was evaluated by automated MIC testing and complementary disk diffusion assays. Transcriptomic and whole-genome sequencing analyses were performed to characterize transcriptional adaptations and virulence- and resistance-associated gene profiles. Co-infection induced a synergistic inflammatory response, with a 6.8-fold increase in neutrophil counts relative to baseline, and caused severe osteolysis, with an approximately 80% reduction in bone-implant contact relative to the sterile group. At postoperative day 7, the co-infection groups showed increased local TNF-α-positive and TRAP-positive areas, supporting an association between the amplified inflammatory response and early osteoclast activation. Spatial analyses revealed asymmetric colonization dynamics: MRSA rapidly disseminated to and colonized PA-contaminated sites by postoperative day 7, whereas reciprocal PA dissemination into MRSA-dominant sites was not detected until day 28. Both pathogens concurrently infiltrated the osteocyte lacuno-canalicular network, uncovering a previously unrecognized reservoir for polymicrobial persistence within bone. Multi-omics profiling revealed susceptibility shifts and extensive adaptive reprogramming in PA. MRSA acts as a dominant ecological driver in PBI that amplifies bone destruction and facilitates polymicrobial persistence, emphasizing the need for multi-species therapeutic strategies. This study establishes a reproducible rat model of polymicrobial bone infection and reveals dynamic MRSA-PA interactions, pathogen-specific ex vivo susceptibility shifts, and polymicrobial occupation of the osteocyte lacuno-canalicular network. These findings highlight the limitations of single-pathogen-based treatment strategies and support the development of multispecies-directed antimicrobial, immunomodulatory, and biofilm-targeting approaches. The model provides a clinically relevant platform for mechanistic studies and preclinical evaluation of diagnostics, therapeutics, drug-delivery systems, and orthopaedic implants.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about zolpidem tartrate